Scholars Central

Conference abstractPublished 7 Jun 2021

Inhibition of parkinson’s disease associated protein hCOMT by bacopa monnieri bioactive compounds-in silico approaches through molecular docking, dynamic simulation and ADMET profiling

Authors: Shyamapada Mandal

University of Gour Banga, India

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Among the aging people neurodegenerative disorders including Parkinson’s disease is of great concern, because of lack of standard cure, and side effects of the currently available medications treating the symptoms of the disease. This suggests the need of new medication for Parkinson’s disease. Brahmi (Bacopa monnieri), a neuroprotective herb, plays a vital role in the treatment of cognitive and aging related disorders, in Ayurvedic medicine. We have assessed Bacopa monnieri bioactive compounds to decipher the inhibition capacity against Parkinson’s disease protein, compared to the currently available Parkinson’s disease medicine, levodopa, by ADMET analysis, molecular docking and dynamic simulation studies. To achieve this goal, we have performed docking of four Bacopa monnieri derived chemical compounds, such as brahmic acid, rosavin, wogonin and oroxindin, compared to levodopa (3D structures downloaded from PubChem), to human catechol O-methyltransferase (hCOMT: PDB ID: 3BWM). The docked protein-ligand complex generated binding energy of -6.6, -7.2, -7.2, -7.7 and -6.1 kcal/mol for brahmic acid, rosavin, wogonin, oroxindin and levodopa, respectively, against hCOMT through hydrogen bond formation and hydrophobic interactions. We have also performed molecular dynamic simulation to authenticate the formation of thermodynamically stable protein-ligand complex due to low free binding energy, and checked the quality of hCOMT structure through Ramachandran plot analysis. Based upon the drug-likeness property, oral bioavailability and ADMET profiles of the Bacopa monnieri derived chemical ligands might be useful in the preparation of biotherapeutics for Parkinson’s disease.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectGenetics & Molecular Biology
  • SubjectNeuroscience & Neurology
  • BylineArticles whose byline prints “Shyamapada Mandal”